Secondary Logo

Journal Logo

You can read the full text of this article if you:

Institutional members access full text with Ovid®


Rifaximin in the Treatment of Irritable Bowel Syndrome

Is There a High Risk for Development of Antimicrobial Resistance?

Farrell, David J. PhD, D(ABMM)

Author Information
Journal of Clinical Gastroenterology: March 2013 - Volume 47 - Issue 3 - p 205-211
doi: 10.1097/MCG.0b013e31827559a3
  • Buy


© 2013 Lippincott Williams & Wilkins, Inc.